Donald Trump’s most consequential trade move of his second term didn’t arrive through Congress or a formal proclamation — it appeared on Truth Social. The former president announced a phased tariff plan on generic drug imports, keeping them tariff‑free for two years, then imposing a 100% tariff, and eventually raising it to 200%. The policy is aimed squarely at India, the world’s largest supplier of generic medicines to the US, with nearly one in two American prescriptions relying on Indian manufacturing.
Trump’s stated goal is to force pharmaceutical production back onto American soil. But analysts warn the likely outcome will be very different: higher drug prices for US patients, supply disruptions, and pressure on insurers and hospitals. India’s pharmaceutical sector, meanwhile, may emerge bruised but largely intact, having weathered tariff threats and regulatory shocks before.
India’s generics industry benefits from decades of scale, low production costs, and a global export network. Even with steep tariffs, US buyers may struggle to find affordable alternatives quickly. Domestic American manufacturing cannot ramp up overnight — especially for complex generics and injectables — meaning the US could face short‑term shortages and long‑term price inflation.
For a president who has repeatedly promised affordable medicine, the trade‑off is striking. Tariffs may appeal politically as a “tough on trade” stance, but economically they risk creating a costly bottleneck in America’s healthcare system. Hospitals, Medicare, and private insurers could all face rising procurement costs, ultimately passing the burden to patients.
India, meanwhile, may redirect exports to Europe, Africa, and Southeast Asia, where demand for low‑cost generics continues to grow.